0001104659-19-032921.txt : 20190530
0001104659-19-032921.hdr.sgml : 20190530
20190530214810
ACCESSION NUMBER: 0001104659-19-032921
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190528
FILED AS OF DATE: 20190530
DATE AS OF CHANGE: 20190530
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vertex Global Healthcare Fund I Pte Ltd.
CENTRAL INDEX KEY: 0001663140
STATE OF INCORPORATION: U0
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38916
FILM NUMBER: 19868408
BUSINESS ADDRESS:
STREET 1: 250 NORTH BRIDGE ROAD
STREET 2: #05-01 RAFFLES CITY TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 179101
BUSINESS PHONE: 6568288088
MAIL ADDRESS:
STREET 1: 250 NORTH BRIDGE ROAD
STREET 2: #05-01 RAFFLES CITY TOWER
CITY: SINGAPORE
STATE: U0
ZIP: 179101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc
CENTRAL INDEX KEY: 0001761612
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
BUSINESS PHONE: 011441223261503
MAIL ADDRESS:
STREET 1: B900 BABRAHAM RESEARCH CAMPUS
CITY: CAMBRIDGE
STATE: X0
ZIP: CB22 3AT
FORMER COMPANY:
FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd
DATE OF NAME CHANGE: 20181212
4
1
a4.xml
4
X0306
4
2019-05-28
0
0001761612
BICYCLE THERAPEUTICS plc
BCYC
0001663140
Vertex Global Healthcare Fund I Pte Ltd.
C/O BICYCLE THERAPEUTICS PLC
B900, BABRAHAM RESEARCH CAMPUS
CAMBRIDGE
X0
CB 22 3AT
UNITED KINGDOM
0
0
1
0
Ordinary Shares
2019-05-28
4
C
0
1272733
A
1272733
D
Ordinary Shares
2019-05-28
4
X
0
141668
A
1414401
D
Ordinary Shares
2019-05-28
4
C
0
206767
A
1621168
D
Series B1 Preferred Shares
2019-05-28
4
C
0
1272733
D
Ordinary Shares
1272733
0
D
Series B1 Preferred Shares Warrants
2019-05-28
4
X
0
141668
D
Ordinary Shares
141668
0
D
Series B2 Preferred Shares
2019-05-28
4
C
0
206767
D
Ordinary Shares
206767
0
D
Each Series B1 and B2 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.
/s/ Chua Kee Lock By:Chua Kee Lock Title: Director
2019-05-30